EGFR Mutational Status and PD-L1 in Early-Stage Brazilian Non-Small-Cell Lung Cancer

被引：0
|
作者：
De Oliveira Cavagna, R. [1 ]
Alves Pinto, I. [1 ]
Virginio Da Silva, A. L. [1 ]
Santana, I. [2 ]
Mourao Dias, J. [3 ]
Souza, L. C. [3 ]
Ferreira Da Silva, F. A. [3 ]
Biazotto Fernandes, M. F. [3 ]
Dix Junqueira Pinto, G. [3 ]
Santos Negreiros, I. [3 ]
Escremim De Paula, F. [4 ]
Noriz Berardinelli, G. [4 ]
Stanfoca Casagrande, G. M. [1 ]
Santiago Goncalves, M. F. [1 ]
Albino Da Silva, E. C. [2 ]
Duval Da Silva, V. [2 ]
De Marchi, P. [5 ]
Vieira Reis, R. M. [1 ]
Ferro Leal, L. [6 ]
机构：
[1] Barretos Canc Hosp, Mol Oncol, Barretos, Brazil
[2] Barretos Canc Hosp, Dept Pathol, Barretos, Brazil
[3] Barretos Canc Hosp, Dept Med Oncol, Barretos, Brazil
[4] Barretos Canc Hosp, Dept Mol Diag, Barretos, Brazil
[5] Oncoclinicas, Rio De Janeiro, Brazil
[6] Barretos Sch Hlth Sci Dr Paulo Prata Facisb, Barretos, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
PD-L1; EGFR; adjuvant therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P57.06
引用
收藏
页码：S1139 / S1139
页数：1
相关论文
共 50 条
  • [21] Perioperative pembrolizumab for early-stage non-small-cell lung cancer
    Bastin, Tom
    Thomas, Quentin Dominique
    BULLETIN DU CANCER, 2024, 111 (11) : 1000 - 1002
  • [22] SURVIVAL IN EARLY-STAGE NON-SMALL-CELL LUNG-CANCER
    NESBITT, JC
    PUTNAM, JB
    WALSH, GL
    ROTH, JA
    MOUNTAIN, CF
    ANNALS OF THORACIC SURGERY, 1995, 60 (02): : 466 - 472
  • [23] Management of early-stage non-small-cell lung cancer (NSCLC)
    Le Chevalier, Thierry
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S292 - S293
  • [24] Accelerated hypofractionation for early-stage non-small-cell lung cancer
    Cheung, PCF
    Yeung, LTF
    Basrur, V
    Ung, YC
    Balogh, J
    Danjoux, CE
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (04): : 1014 - 1023
  • [25] Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors
    Santarpia, Mariacarmela
    Altavilla, Giuseppe
    Pitini, Vincenzo
    Rosell, Rafael
    FUTURE ONCOLOGY, 2015, 11 (08) : 1259 - 1274
  • [26] Clinical factors associated with high PD-L1 expression in patients with early-stage non-small cell lung cancer
    Ohara, Shuta
    Suda, Kenichi
    Hamada, Akira
    Chiba, Masato
    Ito, Masaoki
    Shimoji, Masaki
    Takemoto, Toshiki
    Soh, Junichi
    Tsutani, Yasuhiro
    THORACIC CANCER, 2024, 15 (31) : 2229 - 2234
  • [27] Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer
    Meyers, D. E.
    Bryan, P. M.
    Banerji, S.
    Morris, D. G.
    CURRENT ONCOLOGY, 2018, 25 (04) : E324 - E334
  • [28] Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients
    Papadopoulou, Eirini
    Tsoulos, Nikolaos
    Tsirigoti, Angeliki
    Apessos, Angela
    Agiannitopoulos, Konstantinos
    Metaxa-Mariatou, Vasiliki
    Zarogoulidis, Konstantinos
    Zarogoulidis, Pavlos
    Kasarakis, Dimitrios
    Kakolyris, Stylianos
    Dahabreh, Jubrail
    Vlastos, Fotis
    Zoublios, Charalampos
    Rapti, Aggeliki
    Papageorgiou, Niki Georgatou
    Veldekis, Dimitrios
    Gaga, Mina
    Aravantinos, Gerasimos
    Karavasilis, Vasileios
    Karagiannidis, Napoleon
    Nasioulas, George
    ONCOLOGY LETTERS, 2015, 10 (04) : 2176 - 2184
  • [29] Relationship between PD-L1 Expression and EGFR/HER2 Signaling in Non-Small-Cell Lung Cancer
    Okita, R.
    Maeda, A.
    Shimizu, K.
    Nojima, Y.
    Saisho, S.
    Nakata, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2109 - S2109
  • [30] Monitoring of soluble PD-L1 levels in sera in non-small-cell lung cancer
    Igarashi, Tomoyuki
    Hanaoka, Jun
    Teramoto, Koji
    Daigo, Yataro
    CANCER SCIENCE, 2018, 109 : 1097 - 1097
12345